About SGN-CD19A

SGN-CD19A is an antibody-drug conjugate (ADC) targeting CD19, a protein expressed on acute lymphoblastic leukemia and some types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), as well as on certain healthy cells of the immune system. We have reported preclinical data demonstrating that SGN-CD19A effectively binds to target cells, internalizes and induces potent cell-killing activity and durable tumor regressions at low doses in multiple cancer models.


SGN-CD19A is in phase 1 clinical trials for CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Based on encouraging phase 1 data, a phase 2 trial in relapsed DLBCL is planned.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave